Bristol-Myers Squibb Co.’s $74 billion planned purchase of Celgene Corp. puts it in line to lead the drug industry’s hottest market, cancer, as early as next year.
{iframe}https://www.bloomberg.com/news/articles/2019-01-03/biggest-pharma-deal-ever-propels-bristol-myers-to-cancer-lead{/iframe}